# Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer

> **NCT06134271** · PHASE2 · UNKNOWN · sponsor: **Jianbin Bi** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic Hormone-Sensitive Prostate Cancer

## Interventions

- **DRUG:** Rezvilutamide
- **DRUG:** Rezvilutamide plus abiraterone
- **DRUG:** Continue previous treatment

## Key facts

- **NCT ID:** NCT06134271
- **Lead sponsor:** Jianbin Bi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-15
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06134271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06134271, "Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06134271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*